Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology
The DOI matches its Crossref record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of beta amyloid (Abeta) protein and the formation of neurofibrillary tangles. In addition, there is an increase of inflammatory proteins in the brains of AD patients. Epidemiological studies, indicating that non-steroidal anti-inflammatory drugs (NSAIDs) decrease the risk of developing AD, have encouraged the study on the role of inflammation in AD. The best-characterized action of most NSAIDs is the inhibition of cyclooxygenase (COX). The expression of the constitutively expressed COX-1 and the inflammatory induced COX-2 has been intensively investigated in AD brain and different disease models for AD. Despite these studies, clinical trials with NSAIDs or selective COX-2 inhibitors showed little or no effect on clinical progression of AD. The expression levels of COX-1 and COX-2 change in the different stages of AD pathology. In an early stage, when low-fibrillar Abeta deposits are present and only very few neurofibrillary tangles are observed in the cortical areas, COX-2 is increased in neurons. The increased neuronal COX-2 expression parallels and colocalizes with the expression of cell cycle proteins. COX-1 is primarily expressed in microglia, which are associated with fibrillar Abeta deposits. This suggests that in AD brain COX-1 and COX-2 are involved in inflammatory and regenerating pathways respectively. In this review we will discuss the role of COX-1 and COX-2 in the different stages of AD pathology. Understanding the physiological and pathological role of cyclooxygenase in AD pathology may facilitate the design of therapeutics for the treatment or prevention of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the COX-1 inhibitor naproxen was beneficial in fast decliners only; in contrast, the selective COX-2 inhibitor celecoxib was beneficial in slow decliners but harmful in the fast-progressing group.”
From Microglia in Alzheimer's disease (2017) · cites this paper as [105]
In the citing paper
“epidemiological studies supported that NSAIDs decrease the development of AD (105).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [105]
In the citing paper
“COX-2 expression peaks in neurons in Braak phases 0-II (an early stage characterized by neurofibrillary changes beginning at transentorhinal regions), probably representing an adaptive response that subsequently declines (105).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [105]
Citations
Cites
Still being checked.
Cited by
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Bacchi, S., Palumbo, P., Sponta, A., & Coppolino, M. F. (2012) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152312803476255 · Cited by 433
Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases
Rauf, A., Badoni, H., Abu-Izneid, T., Olatunde, A., Rahman, M. M., Painuli, S., Semwal, P., Wilairatana, P., & Mubarak, M. S. (2022) · Molecules · doi:10.3390/molecules27103194 · Cited by 306
RetractedCarrero, I., Gonzalo, M. R., Martin, B., Sanz-Anquela, J. M., Arévalo-Serrano, J., & Gonzalo-Ruiz, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.05.004 · Cited by 132
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121
“Several mechanisms have been proposed to explain the possible protective effects of NSAIDs in AD, including the reduction of brain inflammation by inhibition of cyclooxygenase (COX)-mediated synthesis of pro-inflammatory prostaglandins [101].”
Background
Metadata
- Authors
- Hoozemans, J., Rozemuller, J., van Haastert, E., Veerhuis, R., & Eikelenboom, P.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-05-01
- Volume
- 14
- Issue
- 14
- Pages
- 1419-1427
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2138214629
- Cited by
- 137
- References
- 0
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 10 · 2021: 4 · 2020: 7 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 5 · 2014: 7 · 2013: 9 · 2012: 10
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Vrije Universiteit Amsterdam
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- Alzheimer's disease, cyclooxygenase-1, cyclooxygenase-2, amyloid-beta, neurofibrillary tangles, neuroinflammation, microglia, cell cycle proteins, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, disease stage, neurodegeneration
- MeSH terms
- Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Humans, Inflammation, Neurons, Amyloid beta-Peptides, Cyclooxygenase Inhibitors, Cell Cycle Proteins, Cyclooxygenase 1, Cyclooxygenase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology. https://app.cochat.ai/papers/10.2174/138161208784480171
- The paper
- Hoozemans, J., Rozemuller, J., van Haastert, E., Veerhuis, R., & Eikelenboom, P. (2008). Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology. Current Pharmaceutical Design. https://doi.org/10.2174/138161208784480171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.